Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma

Gabriel M. Knight, Andrew C. Gordon, Vanessa Gates, Abhinav Talwar, Ahsun Riaz, Riad Salem, Robert Lewandowski*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Yttrium-90 transarterial radioembolization (TARE) has progressed from a salvage or palliative lobar or sequential bilobar regional liver therapy for patients with advanced disease to a versatile, potentially curative, and often highly selective local treatment for patients across Barcelona Clinic Liver Cancer stages. With this shift, radiation dosimetry has evolved to become more tailored to patients and target lesion(s), with treatment dose and distributions adapted for specific clinical goals (ie, palliation, bridging or downstaging to liver transplantation, converting to surgical resection candidacy, or ablative/curative intent). Data have confirmed that “personalizing” dosimetry yields real-world improvements in tumor response and overall survival while maintaining a favorable adverse event profile. In this review, imaging techniques used before, during, and after TARE have been reviewed. Historical algorithms and contemporary image-based dosimetry methods have been reviewed and compared. Finally, recent and upcoming developments in TARE methodologies and tools have been discussed.

Original languageEnglish (US)
Pages (from-to)1214-1225
Number of pages12
JournalJournal of Vascular and Interventional Radiology
Issue number7
StatePublished - Jul 2023

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this